Sedentary Behavior and Health Outcomes Study
SBHO
Metabolic Effects of Interrupting Sedentary Time in Youth In-lab and in Free-living Settings
1 other identifier
interventional
35
1 country
1
Brief Summary
This study is a randomized crossover trial to compare the effectiveness of interrupting SB on glucose homeostasis in the lab and free-living settings. All participants (N=56) will complete one screening visit to determine eligibility, complete at fitness test, and body composition analysis by bioelectrical impedance. After 7-21 days, all participants will complete two 3-hour in-lab oral glucose tolerance tests (spaced 7-21 days apart). Prior to the in-lab OGTT visits, participants will wear an activity monitor for 7 days on the right thigh. The experimental conditions for the OGTTs will be: 1) 3-hour OGTT of continuous sitting; and 2) 3-hour OGTT with sitting interrupted every 30 minutes with 3-minutes of moderate intensity walking on a treadmill. There will be a 7-21 day washout period between the OGTT visits. In addition, a subset of participants (N=12) who meet inclusion criteria and who successfully complete both OGTT visits will complete a second randomized crossover trial in the free-living environment. The experimental conditions for the free-living components will be: 1) 4 days of habitual sedentary behaviors; and 2) 4 days of prompted short exercise breaks during times in which sedentary behaviors have exceeded 30 minutes. Participants in the free-living trial will wear an activity monitor and a continuous glucose monitor.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jan 2018
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 12, 2017
CompletedFirst Posted
Study publicly available on registry
May 15, 2017
CompletedStudy Start
First participant enrolled
January 1, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2020
CompletedNovember 13, 2020
November 1, 2020
2.4 years
May 12, 2017
November 10, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
In-Lab: Metabolic responses
glucose, insulin, and c-peptide area under the curve
3 hours
Free-living: Glucose responses
glucose area under the curve
4 days
Predictors of in-lab glucose responses
Independent-sample t-tests will assess if mean in-lab glucose AUC differs within experimental condition by weight status (normal weight or overweight/obese). Independent-sample t-tests will assess if mean AUC values between conditions (delta AUC) differ by weight status. Structural equation models of latent growth curves will be used to assess the relationship between BMI z-score trajectories in the preceding 3 years, in-lab glucose AUC responses by experimental condition. Specifically, models will test if a) the higher the initial BMI z score (year 1), the higher the initial serum value (-10 min); b) the higher the initial BMI z score (year 1), the greater the change in serum AUC between experimental conditions; and c) the greater slope of the BMI z score change, the greater the change in serum AUC between experimental conditions.
3 years
Individual variations in glucose responses in-lab
Mixed-effects location scale models (MIXREGLS) will test how between-subject (BS) and within-subject (WS) variation in SB in the preceding 3 years are associated with glucose responses to in-lab SB interruptions. The predictors are average 3-year SB level and SB level at each year (variation in SB). The Stage 1 mixed-effects location scale model will examine random effects of between-subject variance (i.e., location) and of within-subject variance (i.e., scale), sex, baseline percent body fat, and baseline age. The Stage 2 model will assess how these variance sources from Stage 1 affect the delta AUC between in-lab prolonged SB and SB interruptions with regards to glucose (the WS effects).
3 years
Secondary Outcomes (1)
Relationship between in-lab and free-living glucose AUC
5 days
Study Arms (2)
Sitting Only (SIT)
PLACEBO COMPARATORIn-Lab (full sample): children will sit continuously for 3 hours during an OGTT Free-living (sub-sample; N=12): children will complete their habitual sedentary behaviors over 4 days; they will also wear a continuous glucose monitor
Walking Breaks (WALK)
EXPERIMENTALIn-Lab (full sample): children will be asked to walk on a treadmill every 30 minutes for 3 minute bouts during a 3 hour OGTT Free-living (sub-sample; N=12): children will be prompted with an ActivPAL vtap monitor on the right thigh to perform 3-minute walking bouts whenever sedentary time has lasted longer than 30 minutes over 4 days; they will also wear a continuous glucose monitor
Interventions
In-Lab (full sample): participants will be asked to walk on a treadmill for 3 minutes every 30 minutes at a moderate pace during a 3-hour OGTT Free-living (sub-sample; N=12): participants will be prompted via an ActivPAL vtap monitor to walk for 3 minutes every time sedentary behavior lasts longer than 30 continuous minutes
In-Lab (full sample): participants will remain seated for 3 hours during an OGTT Free-living (sub-sample; N=12): participants will perform their habitual sedentary behaviors
Eligibility Criteria
You may qualify if:
- current/past participant in the MATCH Study
- good general health
- fasting plasma glucose \<100 mg/dL
- BMI greater than the 5th percentile
You may not qualify if:
- significant cardiac or pulmonary disease likely to or resulting in hypoxia or decreased perfusion
- evidence of impaired glucose tolerance or type 2 diabetes
- presence of other endocrinologic disorders leading to obesity (e.g.: Cushing Syndrome)
- current or past anti-psychotic drugs use that would affect metabolism
- non-diet treatment for hypertension or dyslipidemia
- precocious puberty and/or receiving androgen and estrogen therapy
- medication use known to affect body composition/weight
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Southern California Keck School of Medicine
Los Angeles, California, 90032, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Britni R Belcher, PhD, MPH
University of Southern California
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor of Preventive Medicine
Study Record Dates
First Submitted
May 12, 2017
First Posted
May 15, 2017
Study Start
January 1, 2018
Primary Completion
June 1, 2020
Study Completion
June 30, 2020
Last Updated
November 13, 2020
Record last verified: 2020-11
Data Sharing
- IPD Sharing
- Will not share
We do not intend to share IPD with other researchers outside of our study.